Igor Puzanov
Roswell Park Comprehensive Cancer Center(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, Renal cell carcinoma treatment
Most-Cited Works
- → Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline(2018)3,616 cited
- → Inhibition of Mutated, Activated BRAF in Metastatic Melanoma(2010)3,526 cited
- → Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations(2012)2,783 cited
- → Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma(2015)2,539 cited
- → Fulminant Myocarditis with Combination Immune Checkpoint Blockade(2016)2,219 cited
- → Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab(2014)2,197 cited
- → Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib(2012)2,141 cited
- → Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group(2017)1,943 cited
- → Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma(2010)1,815 cited
- → Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations(2015)1,714 cited